<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Nakanishi T</submitter><funding>MEXT | Japan Society for the Promotion of Science</funding><funding>Public Health Agency of Canada</funding><funding>Cancer Research UK</funding><funding>Medical Research Council</funding><funding>Fonds de Recherche du Québec - Santé</funding><funding>National Institute for Health Research (NIHR)</funding><funding>Canada Foundation for Innovation</funding><funding>Wellcome Trust</funding><funding>Gouvernement du Canada | Canadian Institutes of Health Research</funding><pagination>6198</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10550956</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>14(1)</volume><pubmed_abstract>Alternative splicing generates functional diversity in isoforms, impacting immune response to infection. Here, we evaluate the causal role of alternative splicing in COVID-19 severity and susceptibility by applying two-sample Mendelian randomization to cis-splicing quantitative trait loci and the results from COVID-19 Host Genetics Initiative. We identify that alternative splicing in lung, rather than total expression of OAS1, ATP11A, DPP9 and NPNT, is associated with COVID-19 severity. MUC1 and PMF1 splicing is associated with COVID-19 susceptibility. Colocalization analyses support a shared genetic mechanism between COVID-19 severity with idiopathic pulmonary fibrosis at the ATP11A and DPP9 loci, and with chronic obstructive lung diseases at the NPNT locus. Last, we show that ATP11A, DPP</pubmed_abstract><journal>Nature communications</journal><pubmed_title>Alternative splicing in lung influences COVID-19 severity and respiratory diseases.</pubmed_title><pmcid>PMC10550956</pmcid><funding_grant_id>221680/Z/20/Z</funding_grant_id><funding_grant_id>365825; 409511, 100558, 169303</funding_grant_id><funding_grant_id>C18281/A29019</funding_grant_id><funding_grant_id>22KJ1190, 22J30004, 23H02917</funding_grant_id><funding_grant_id>476575</funding_grant_id><pubmed_authors>Richards JB</pubmed_authors><pubmed_authors>Willett J</pubmed_authors><pubmed_authors>Guillen-Guio B</pubmed_authors><pubmed_authors>Allen RJ</pubmed_authors><pubmed_authors>Zhou S</pubmed_authors><pubmed_authors>Adra D</pubmed_authors><pubmed_authors>Nakanishi T</pubmed_authors><pubmed_authors>Farjoun Y</pubmed_authors></additional><is_claimable>false</is_claimable><name>Alternative splicing in lung influences COVID-19 severity and respiratory diseases.</name><description>Alternative splicing generates functional diversity in isoforms, impacting immune response to infection. Here, we evaluate the causal role of alternative splicing in COVID-19 severity and susceptibility by applying two-sample Mendelian randomization to cis-splicing quantitative trait loci and the results from COVID-19 Host Genetics Initiative. We identify that alternative splicing in lung, rather than total expression of OAS1, ATP11A, DPP9 and NPNT, is associated with COVID-19 severity. MUC1 and PMF1 splicing is associated with COVID-19 susceptibility. Colocalization analyses support a shared genetic mechanism between COVID-19 severity with idiopathic pulmonary fibrosis at the ATP11A and DPP9 loci, and with chronic obstructive lung diseases at the NPNT locus. Last, we show that ATP11A, DPP</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Oct</publication><modification>2026-05-29T07:13:30.511Z</modification><creation>2024-11-15T01:39:35.833Z</creation></dates><accession>S-EPMC10550956</accession><cross_references><pubmed>37794074</pubmed><doi>10.1038/s41467-023-41912-4</doi></cross_references></HashMap>